Decrease of prostaglandin I2 binding sites in thyroid cancer.

Por Virgolini, I., Hermann, M., Sinzinger, H.
Publicado em 1988

Human hepatocellular cancers show decreased prostaglandin E1 binding capacity.

Por Virgolini, I., Sinzinger, H., Müller, C., Hermann, M.
Publicado em 1989

Stabilization of endothelial lining and decrease in circulating endothelial cells--one mechanism underlying the clinical action of PGE1?

Por Sinzinger, H, Virgolini, I, Fitscha, P, Rauscha, F, Kaliman, J
Publicado em 1988

Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations.

Por Li, S. R., Yang, Q., Wandl, E., Pirker, W., Virgolini, I.
Publicado em 1993

99mTc-neoglycoalbumin (NGA)-binding to human hepatic binding protein (HBP) in vitro.

Por Virgolini, I, Angelberger, P, Müller, C, O'Grady, J, Sinzinger, H
Publicado em 1990

Prostaglandin E1 decreases the low-density-lipoprotein entry into rabbit arterial wall.

Por Sinzinger, H., Virgolini, I., Lupattelli, G., Molinari, E., Gerakakis, A., Angelberger, P.
Publicado em 1991

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.

Por Raderer, M., Kurtaran, A., Hejna, M., Vorbeck, F., Angelberger, P., Scheithauer, W., Virgolini, I.
Publicado em 1998

Diagnostic Value of Software-Based Image Fusion of Computed Tomography and F18-FDG PET Scans in Patients with Malignant Lymphoma

Por Henninger, B., Putzer, D., Kendler, D., Uprimny, C., Virgolini, I., Gunsilius, E., Bale, R.
Publicado em 2012

Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.

Por Virgolini, I., Müller, C., Klepetko, W., Angelberger, P., Bergmann, H., O'Grady, J., Sinzinger, H.
Publicado em 1990

Improved Quality of Life in Patients Treated with Peptide Radionuclides

Por Traub-Weidinger, T, Raderer, M., Uffmann, M., Angelberger, P., Kurtaran, A., Leimer, M., Preitfellner, J., Dudczak, R., Virgolini, I.
Publicado em 2011

Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer.

Por Virgolini, I., Kornek, G., Höbart, J., Li, S. R., Raolerer, M., Bergmann, H., Scheithauer, W., Pantev, T., Angelberger, P., Sinzinger, H.
Publicado em 1993

P06.04 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) WITH (90)Y-DOTATOC TARGETING OF RECURRENT ATYPICAL MENINGIOMA: A CASE REPORT

Por Iglseder, S., Nowosielski, M., Muigg, A., Stockhammer, G., Freyschlag, C., Lanbach, J., Nevinny-Stickel, M., Buxbaum, S., Uprimny, C., Virgolini, I.
Publicado em 2014

Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type

Por Raderer, M, Traub, T, Formanek, M, Virgolini, I, Österreicher, C, Fiebiger, W, Penz, M, Jäger, U, Pont, J, Chott, A, Kurtaran, A
Publicado em 2001

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results

Por Raderer, M, Hamilton, G, Kurtaran, A, Valencak, J, Haberl, I, Hoffmann, O, Kornek, G V, Vorbeck, F, Hejna, M H L, Virgolini, I, Scheithauer, W
Publicado em 1999